相关实验视频

Updated: Jan 6, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

ABCB1和ABCC10多态预测EGFR突变NSCLC中对第一代和第三代EGFR-TKI的敏感性

Sanae Toda-Shiraga¹, Takehiro Uemura², Akihito Kakihara¹

¹Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya, Aichi, 467-8601, Japan.

Investigational new drugs

|December 4, 2025

概括

在ATP结合盒 (ABC) 载体基因的遗传变异可以预测非小细胞肺癌 (NSCLC) 治疗反应. 特定的单核酸多态 (SNP) 与表皮生长因子受体 (EGFR) - 铁氨酸激酶抑制剂 (TKI) 敏感性相关,有助于个性化医疗.

科学领域:

药物基因组学药物基因组学
分子瘤学分子瘤学
癌症生物标志物癌症生物标志物

背景情况:

非小细胞肺癌 (NSCLC) 治疗疗效不同.
ATP结合盒 (ABC) 载体会影响药物反应.
表皮生长因子受体 (EGFR) 氨酸激酶抑制剂 (TKI) 是NSCLC的关键疗法.

研究的目的:

调查ABC载体基因多态性和NSCLC中的EGFR-TKI敏感性之间的关联.
为了确定潜在的遗传生物标志物来预测治疗疗效.

主要方法:

在16个NSCLC细胞系中实时PCR量化ABC载体mRNA表达.
格菲提尼布和奥西默提尼布的IC50值与mRNA表达相关.
在细胞系和患者血液样本中分析了ABC载体基因中的单核酸多态 (SNP).
分析了109名第一代和54名第三代EGFR-TKI治疗患者的临床数据.

主要成果:

在细胞系中,ABC载体mRNA表达和EGFR-TKI敏感性之间没有显著的相关性.
特定的ABC载体SNP在体外显示与药物细胞毒性有显著的相关性.
ABCB1 C1236T T/T基因型与第一代EGFR-TKIs的无进展生存时间 (PFS) 有关.
在接受第三代EGFR-TKI的患者中,ABCC10 T2843C T/T基因型与更长的PFS有关.

结论:

在ABC载体基因多态,特别是SNP,显示潜在的EGFR-TKI在NSCLC的有效性预测生物标志物.
这些发现支持在个性化NSCLC治疗策略中使用药物基因组学.
需要进一步验证才能将这些SNP纳入临床实践,以改善患者的治疗结果.

关键词:

携带ATP结合性磁带的传送器皮肤上生长因子受体-铁氨酸激酶抑制剂.肺癌是一种肺癌.单个核酸的多态性.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...